Medroxyprogesterone caproate

Medroxyprogesterone caproate (MPC) is a progestin and a progestogen ester which was synthesized in 1958 but was never marketed.[1][2] It has been confused with hydroxyprogesterone caproate (OHPC) and medroxyprogesterone acetate (MPA) in a number of publications.[3][4][5][6][7][8][9][10][11][12] In addition to MPA and OHPC, analogues of MPC include chlormadinone caproate, gestonorone caproate, megestrol caproate, and methenmadinone caproate.

Not to be confused with Hydroxyprogesterone caproate or Medroxyprogesterone acetate.
Medroxyprogesterone caproate
Clinical data
Other namesMPC; Medroxyprogesterone capronate; Medroxyprogesterone hexanoate; 6α-Methyl-17α-hydroxyprogesterone hexanoate; 6α-Methyl-17α-hydroxypregn-4-ene-3,20-dione hexanoate
Routes of
administration		Intramuscular injection
Drug classProgestogen; Progestin; Progestogen ester
Identifiers
IUPAC name
  • [(6S,8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H42O4
Molar mass442.640 g·mol−1
3D model (JSmol)
SMILES
  • CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H](C4=CC(=O)CC[C@]34C)C)C)C(=O)C
InChI
  • InChI=1S/C28H42O4/c1-6-7-8-9-25(31)32-28(19(3)29)15-12-23-21-16-18(2)24-17-20(30)10-13-26(24,4)22(21)11-14-27(23,28)5/h17-18,21-23H,6-16H2,1-5H3/t18-,21+,22-,23-,26+,27-,28-/m0/s1
  • Key:RDNJGIAWTAMGGM-UPIZIACDSA-N

See also

References
  1. Babcock, John C.; Gutsell, Erwin S.; Herr, Milton E.; Hogg, John A.; Stucki, Jacob C.; Barnes, Lester E.; Dulin, William E. (1958). "6α-Methyl-17α-hydroxyprogesterone 17-acylates; a new class of potent progestins". Journal of the American Chemical Society. 80 (11): 2904–2905. doi:10.1021/ja01544a079. ISSN 0002-7863.
  2. Barton, D. H. R.; Taylor, W. C. (1958). "510. Photochemical transformations. Part IV. The photochemistry of prednisone acetate". Journal of the Chemical Society (Resumed): 2500. doi:10.1039/jr9580002500. ISSN 0368-1769.
  3. Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella J (April 1998). "Progestins and breast cancer". J. Steroid Biochem. Mol. Biol. 65 (1–6): 225–35. doi:10.1016/S0960-0760(98)00028-4. PMID 9699877. S2CID 28416130.
  4. Pasqualini JR, Ebert C (June 1999). "Biological effects of progestins in breast cancer". Gynecol. Endocrinol. 13 Suppl 4: 11–9. doi:10.1080/gye.13.s4.11.19. PMID 12227897.
  5. Pasqualini JR, Chetrite GS (December 2010). "Biological responses of progestogen metabolites in normal and cancerous human breast". Horm Mol Biol Clin Investig. 3 (3): 427–35. doi:10.1515/HMBCI.2010.066. PMID 25961215. S2CID 41680565.
  6. Lantta M, Kahanpää K, Kärkkäinen J, Lehtovirta P, Wahlström T, Widholm O (June 1984). "Estradiol and progesterone receptors in two cases of endometrial stromal sarcoma". Gynecol. Oncol. 18 (2): 233–9. doi:10.1016/0090-8258(84)90031-3. PMID 6735266.
  7. Saul Bernard Gusberg; Hugh M. Shingleton; Gunter Deppe (1988). Female genital cancer. Churchill Livingstone. p. 374. ISBN 978-0-443-08525-3.
  8. Proceedings. American Cancer Society and National Cancer Institute of the U.S. Public Health Service, Federal Security Agency. 1970. p. 376.
  9. David H. Nichols; John R. Evrard (1985). Ambulatory Gynecology. Harper & Row. p. 518. ISBN 978-0-06-141815-0.
  10. Louis Sanford Goodman; Alfred Goodman Gilman (1996). Goodman & Gilman's the Pharmacological Basis of Therapeutics. McGraw-Hill, Health Professions Division. pp. 1427, 1823, 1858. ISBN 978-0-07-026266-9.
  11. Endokrinologie. Johann Ambrosius Barth Verlag. 1969. p. 431.
  12. McKinnon AO, Tarrida Del Marmol Figueroa S, Nobelius AM, Hyland JH, Vasey JR. Failure of medroxyprogesterone caproate to maintain pregnancy in ovariectomised mares. Equine Vet J 1993; 25:158–160.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.